Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

Aerpio Pharmaceuticals, Inc. ARPO, a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Founder, Joseph Gardner, Ph.D., will present at the Oppenheimer 28^th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y. Dr. Gardner will provide a corporate overview and business update.

The presentation will be webcast live and may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company's lead compound, AKB‐9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit www.aerpio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180315005395/en/